美國雇主考慮減少對減肥藥物的承保範圍
US employers consider reducing coverage for weight-loss drugs
Updated at: August 31, 2026 at 12:30 AM
美國醫療福利的前景目前正處於針對 Wegovy 和 Zepbound 等 GLP-1 減重藥物的拉鋸戰中。
The landscape of U.S. healthcare benefits is currently defined by a tug-of-war over GLP-1 weight-loss drugs like Wegovy and Zepbound.
雖然這些藥物在臨床上取得了顯著成效，但也對企業預算造成了巨大壓力。
While these medications have shown remarkable clinical success, they have also placed an immense strain on corporate budgets.
由於每位病患的每月成本通常超過 1,000 美元，許多雇主正在重新評估其承保策略，因為這些藥物已成為藥房支出增加的主要驅動因素。
With monthly costs often exceeding $1,000 per patient, many employers are re-evaluating their coverage strategies as these drugs become a primary driver of rising pharmacy expenses.
目前，雖然超過 90% 的公司將這些藥物納入第二型糖尿病的承保範圍，但僅有少數公司專門提供肥胖症的承保。
Currently, while over 90% of companies cover these drugs for Type 2 diabetes, only a minority provide coverage specifically for obesity.
趨勢正在轉變：在過去一年中，由於公司在面對長期財務回報的不確定性時感到困難，提供 GLP-1 減重承保的雇主數量有所下降。
The trend is shifting: in the past year, the number of employers covering GLP-1s for weight loss has dropped as companies struggle with uncertainty regarding long-term financial returns.
許多雇主並未選擇完全剔除，而是轉向嚴格的利用率管理，例如強制輔導或事先授權要求。
Rather than full elimination, many are turning to strict utilization management, such as mandatory coaching or prior authorization requirements.
這為人力資源主管帶來了艱難的平衡挑戰，他們必須在員工對藥物獲取的高需求與財務永續性的需求之間進行權衡。
This creates a difficult balance for HR leaders, who must navigate intense employee demand for access against the need for financial sustainability.
